Guide · 7 min
Your Gut and Your Hayfever Are More Connected Than You Think
The science linking your microbiome to allergic inflammation — and what you can actually do about it
In short
Lower gut microbiome α-diversity is consistently associated with increased risk and severity of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis, across multiple systematic reviews, cohort studies, and meta-analyses spanning infancy through adulthood. Compositional…
How the trillions of bacteria living in your digestive system quietly shape your allergic responses — and what you can actually do about it
If you've ever wondered why some people sail through pollen season without a single sniff while others are floored by it, the answer may lie somewhere you'd never think to look: your gut. Not your nose, not your lungs — your digestive system. Over the last decade, a growing body of research has begun to reveal a remarkable biological conversation happening between the trillions of microorganisms in your intestines and the immune cells that decide, every day, whether to overreact to harmless pollen or quietly let it pass. Understanding that conversation — and learning how to support it — could genuinely change how you experience allergy season.
The Science: A Gut-Immune Axis You Never Knew You Had
Your gut is home to roughly 38 trillion microbial cells — bacteria, fungi, viruses — collectively known as the gut microbiome. Far from being passive passengers, these microorganisms are in constant dialogue with your immune system, training it, calibrating it, and helping it decide what to attack and what to tolerate. When that microbial community becomes disrupted — a state called dysbiosis — those immune calibrations can go wrong in ways that manifest as allergic disease.
Multiple prospective cohort studies and systematic reviews now consistently link lower gut microbiome diversity, particularly a metric called α-diversity (the richness of different species within an individual), to increased risk of allergic rhinitis, asthma, atopic dermatitis, and food allergy (Simonyté Sjödin et al., 2016; Mousavian et al., 2024). Specific bacterial shortfalls appear repeatedly in the research: lower levels of Bacteroides, Prevotella, Faecalibacterium prausnitzii, and Coprococcus are characteristic of the allergic gut, while an enrichment of pro-inflammatory species like Ruminococcus gnavus seems to make matters worse (Gallant et al., 2025).
But how does a shortage of gut bacteria end up affecting your nose?
The SCFA Pathway
The key mediators appear to be short-chain fatty acids (SCFAs) — particularly butyrate, propionate, and acetate. These small molecules are produced when fibre-fermenting bacteria in your colon break down dietary fibre. They are not just metabolic byproducts; they are potent immune signals.
SCFAs act through two main molecular routes: inhibiting an enzyme called HDAC (histone deacetylase), which controls gene expression in immune cells, and activating G-protein-coupled receptors (FFA2, FFA3, and GPR109a) on the surface of gut and immune cells (Sasaki et al., 2024; Cait et al., 2017). The downstream effects are significant: SCFAs promote the differentiation of regulatory T cells (Tregs) — the immune system's peacekeepers, responsible for dampening overreactive responses — while simultaneously suppressing the Th2-skewed inflammatory signals (IL-4, IL-5, IL-13, IgE) that characterise hayfever. They also strengthen the integrity of the gut epithelial lining, making it harder for allergens to slip through into the bloodstream and trigger sensitisation.
Studies consistently find lower faecal SCFA levels in people with allergic diseases compared to healthy controls, and animal models have shown that dietary interventions restoring SCFA-producing bacteria during pregnancy can reduce allergic airway disease in offspring (Cait et al., 2017).
The Critical Early-Life Window
The timing of microbiome development turns out to matter enormously. Birth cohort studies — including the COPSAC and CHILD cohorts — show that gut dysbiosis in the first weeks and months of life significantly raises the odds of allergic rhinitis in childhood and beyond (Mousavian et al., 2024; García-Mauriño Alcazar et al., 2022). Specifically, reduced Bifidobacterium abundance and elevated Escherichia/Shigella and Clostridium species at just three months of age have been linked to allergic rhinitis diagnoses years later — one cohort tracked this association out to 13 years (Sameeha et al., 2025).
Early-life antibiotic use compounds this risk significantly. Systematic reviews confirm that the more antibiotic courses a child receives, particularly in the first year of life, the greater their risk of developing atopic disease (Sameeha et al., 2025; Obiakor et al., 2018). The mechanism is straightforward: broad-spectrum antibiotics deplete SCFA-producing bacteria like Ruminococcaceae, shrink overall microbial diversity, and disrupt the immune programming that happens during the critical early developmental window — programming that may not be fully recoverable.
Can Probiotics Actually Help?
Given all this, the logical question is: can you restock your gut with beneficial bacteria and improve your hayfever? The honest answer is: modestly, yes — particularly if you're a child or adolescent, and particularly with multi-strain formulations.
Meta-analyses of randomised controlled trials show that probiotics reduce allergic rhinitis symptom scores — with a standard mean difference of around −0.85 for total nasal symptom scores in children — and cut allergy incidence by roughly 25% (Luo et al., 2022; Farahmandi et al., 2022). The best-supported strains include Lactobacillus rhamnosus HN001 and GG, Bifidobacterium lactis HN019, and B. breve M-16V (Kang et al., 2017). These work by restoring Th1/Th2 balance, reducing IgE levels and eosinophil counts, raising anti-inflammatory IL-10, and improving gut barrier integrity.
The picture in adults is more mixed. Several individual-strain trials have failed to reach statistical significance for nasal symptom reduction, and multi-strain formulations used as adjuncts to standard antihistamine or nasal steroid therapy tend to outperform single-strain approaches used alone (Yan et al., 2022). Effects also appear to improve with duration — sustained use of two or more years shows stronger benefit.
What About Fermented Foods?
Fermented foods — yoghurt, kefir, kimchi, sauerkraut, kombucha — are frequently discussed in this context, and there is some genuine evidence worth considering. A well-designed Stanford RCT found that 10 weeks of high fermented food consumption reduced 19 of 93 measured inflammatory proteins, including IL-6 and IL-12b, and measurably increased gut microbiota diversity (Spencer et al., 2022). These are real, meaningful immune effects.
However — and this is an important caveat — no trials have been conducted specifically in allergic rhinitis or atopic disease populations. The tolerance-specific mechanisms (Treg induction, IgA secretion) that would be most relevant to hayfever have not been directly measured in humans following fermented food consumption. The plausibility is there; the direct clinical evidence is not yet.
What This Means for You
If you're an adult living with hayfever, the microbiome research has several practically relevant implications.
First, your gut is a genuine part of your allergy biology — not a peripheral consideration. The immune skewing that makes you reactive to grass pollen in June is partly shaped by the microbial community you've been building (or depleting) since birth.
Second, lifestyle factors you control today influence that community. A diet rich in diverse plant fibres feeds SCFA-producing bacteria. Fermented foods increase microbial diversity. Judicious antibiotic use — avoiding unnecessary courses — protects against dysbiosis. None of these are dramatic interventions, but cumulatively they support the gut environment that keeps your immune system better balanced.
Third, if you're a parent of a young child with a family history of atopy, the early-life microbiome data suggests that the first year of life is a particularly meaningful window. This doesn't mean avoiding all antibiotics when they're genuinely needed — it means being informed, asking questions, and where appropriate discussing whether a course is truly necessary with your GP.
The Evidence Landscape: What We Know and What We Don't
It's important to be honest about what the science currently can and cannot tell us.
The association between lower gut diversity and allergic disease is well-established across multiple cohorts and systematic reviews. The mechanistic pathways — SCFAs, Treg induction, Th2 suppression — are well-characterised in animal models and increasingly supported in human observational data. The modest benefit of probiotics for allergic rhinitis, particularly in children, is supported by meta-analysis.
What remains genuinely uncertain:
- Causal direction. Does dysbiosis cause allergic disease, or does allergic disease cause dysbiosis? This chicken-and-egg problem hasn't been fully resolved. It's likely bidirectional, but the proportional contribution of each direction remains unclear.
- Adult-specific data. Almost all the strongest microbiome-allergy evidence comes from paediatric cohorts. Whether microbiome modulation in adulthood offers equivalent benefits to early-life interventions is largely unknown.
- Strain and dose specificity. Not all probiotics are created equal. The evidence is strongest for specific strains at specific doses, and the research landscape is fragmented by enormous heterogeneity in trial design.
- Rhinitis-specific microbiome data. Much of the mechanistic and interventional evidence is drawn from asthma and eczema research, with allergic rhinitis-specific data significantly underrepresented. Extrapolation is reasonable but not proven.
- Fermented foods and allergy. Plausible, promising, but not yet clinically tested in atopic populations.
What Haelo Recommends
Based on the current evidence, here's how to think about your gut health as part of your overall hayfever management:
1. Eat more diverse plant fibre, consistently. Beans, lentils, whole grains, vegetables, fruits, and nuts feed the SCFA-producing bacteria that support regulatory immune function. Aim for 30 different plant foods per week — a target supported by microbiome diversity research.
2. Consider a multi-strain probiotic containing Lactobacillus and Bifidobacterium species. The evidence is strongest for combinations rather than single strains. Use it consistently (ideally year-round, not just during pollen season) and as a complement to — not a replacement for — your usual hayfever medication.
3. Incorporate fermented foods regularly. Yoghurt, kefir, kimchi, sauerkraut, and miso are low-risk, broadly anti-inflammatory additions to your diet. The evidence that they directly reduce hayfever symptoms is weak, but the evidence that they increase gut diversity and reduce systemic inflammation is real.
4. Be thoughtful about antibiotics. This isn't about refusing antibiotics when you genuinely need them — it's about having an informed conversation with your doctor about whether they're necessary in ambiguous cases. If you do need a course, consider supporting your microbiome with probiotics during and after treatment.
5. Don't expect a gut overhaul to replace your antihistamines — yet. The microbiome evidence is genuinely exciting, but it currently supports gut health as a contributing factor in your allergy biology, not a standalone cure. The most effective approach combines microbiome support with personalised pollen tracking, appropriate medication, and environmental awareness.
Your gut and your immune system are in a constant, evolving conversation. The more you understand that conversation — and the more you support the right participants in it — the better placed you are to manage what hayfever throws at you.
Evidence ratings used in this article reflect the current state of published research. Microbiome science is a rapidly evolving field — Haelo will update guidance as new evidence emerges.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
How does gut microbiome diversity affect allergies?
Lower gut microbiome α-diversity is consistently associated with increased risk and severity of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis, across multiple systematic reviews, cohort studies, and meta-analyses spanning infancy through adulthood. Compositional shifts characterized by reduced Actinobacteria and Clostridiaceae alongside enrichment of Bacteroidetes and genera such as Shigella and Prevotella are recurrently observed in allergic individuals. Mendelian randomization studies further suggest causal relationships for specific taxa (e.g., Bifidobacterium increasing risk; Dorea decreasing risk), though directionality remains complex.
How it works
Gut dysbiosis promotes Th2-skewed immune responses by disrupting Th1/Th2/Treg balance, partly through reduced production of short-chain fatty acids (SCFAs) such as butyrate and acetate, which normally support intestinal barrier integrity and Foxp3+ regulatory T cell activity. Additionally, the gut-lung/gut-nose axis transmits systemic inflammatory signals, while disrupted microbial metabolic pathways (e.g., pyruvate biosynthesis, pantothenate/CoA metabolism) further amplify immune dysregulation and allergen hypersensitivity.
Confidence: moderate
Which bacteria reduce allergic response?
Multiple gut bacterial taxa—particularly Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium lactis, and Bifidobacterium bifidum—are associated with reduced allergic rhinitis symptoms and lower allergic sensitization risk, supported by observational studies, preliminary RCTs, and Mendelian randomization analyses. Patients with allergic rhinitis consistently show reduced gut microbial diversity and depleted levels of these protective taxa compared to healthy controls, suggesting dysbiosis plays a role in disease pathogenesis. Meta-analyses and systematic reviews (e.g., Liu et al. 2023) confirm that microbiome supplementation with these strains produces measurable symptom improvements, though effect sizes and optimal strains remain incompletely defined.
How it works
Protective bacteria modulate immune tolerance primarily through short-chain fatty acid (SCFA) production from fiber fermentation, which promotes Foxp3+ regulatory T cells (Tregs) and suppresses Th2-skewed allergic inflammation, thereby reducing IgE production and pro-inflammatory cytokine release. Additionally, aromatic lactate-producing Bifidobacterium species generate 4-hydroxyphenyllactate, directly inhibiting allergen-specific IgE synthesis, while Lactobacillus strains downregulate inflammatory cytokine expression in nasal mucosa and enhance gut barrier integrity.
Confidence: moderate
Do short-chain fatty acids reduce allergic inflammation?
Short-chain fatty acids (SCFAs), particularly butyrate, acetate, and propionate, demonstrate consistent anti-inflammatory effects in preclinical allergic models, including 30-50% reductions in IL-4-producing CD4+ T cells and IgE levels, alongside inhibition of ILC2-dependent airway inflammation. Clinical and observational evidence links lower fecal SCFA levels to increased food allergy risk and Th2 skewing in children, supporting biological plausibility in humans. However, evidence specific to allergic rhinitis remains scarce, and no large human RCTs have yet confirmed therapeutic benefit of SCFA supplementation for allergic disease outcomes.
How it works
SCFAs bind G-protein-coupled receptors (GPR43, GPR41, GPR109A) on immune cells to promote tolerogenic macrophages, suppress Th2 cytokines (IL-4, IL-13), and inhibit mast cell degranulation; butyrate additionally inhibits histone deacetylases (HDACs), upregulating regulatory T cell activity and tight-junction proteins to reinforce the gut epithelial barrier and limit allergen sensitization.
Confidence: moderate
Can probiotics reduce hayfever symptoms?
Multiple systematic reviews and meta-analyses of RCTs indicate that specific probiotics can modestly reduce allergic rhinitis (hay fever) symptoms, particularly nasal symptoms and quality-of-life measures during peak pollen season. A 2022 meta-analysis of 22 RCTs confirmed significant pooled benefits for nasal symptom scores and QoL, though effect sizes vary considerably by strain, dose, and population. Intention-to-treat analyses frequently show attenuated or non-significant effects due to high dropout rates (~33%), while per-protocol analyses of adherent participants demonstrate clearer benefits.
How it works
Probiotics modulate the gut-immune axis by shifting Th2-dominant allergic responses (characterized by elevated IgE and eosinophilia) toward a more balanced Th1 profile, reducing systemic and local nasal inflammation. This occurs through gut microbiota-mediated alterations in systemic immune signaling, though direct stool microbiome compositional changes are often not statistically significant in trials.
Confidence: moderate
What role does early childhood microbiome play?
Early childhood gut microbiome development, particularly during the first 1000 days of life, plays a significant role in allergic rhinitis risk through immune programming established by microbial colonization patterns. Dysbiosis characterized by reduced Bifidobacteria, lower alpha-diversity, and delayed microbiome maturation is consistently associated with Th2-skewed immune responses and increased allergen-specific IgE, elevating atopy and allergic rhinitis risk. Multiple systematic reviews and prospective cohort studies (including the CHILD cohort) corroborate that early antibiotic exposure, cesarean delivery, and abbreviated breastfeeding disrupt protective microbial succession and heighten allergic disease incidence.
How it works
Commensal microbes such as Bifidobacteria promote tolerogenic immune programming by supporting regulatory T-cell activity and suppressing Th2 dominance; their metabolites (e.g., 4-hydroxyphenyllactate) directly attenuate allergen-specific IgE production, while dysbiosis impairs this gut–lung axis immune regulation, facilitating allergic sensitization.
Confidence: moderate
Do antibiotics increase allergy risk?
Early-life antibiotic exposure is consistently associated with increased risk of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy, with the strongest associations occurring during infancy and the first few years of life. Multiple systematic reviews and meta-analyses spanning large cohorts (e.g., 340,428 patients across 34 studies) support this association, with dose-dependent effects observed—broader-spectrum and multiple antibiotic courses confer greater risk. However, evidence is predominantly observational, and residual confounding (particularly 'confounding by indication,' where underlying infections rather than antibiotics drive allergy risk) remains a significant methodological concern.
How it works
Antibiotics disrupt the developing gut microbiome by reducing bacterial diversity and depleting beneficial genera such as Bifidobacteria and Lactobacillus while promoting Proteobacteria overgrowth, leading to increased intestinal permeability, reduced short-chain fatty acid production, and a Th2-skewed immune response that promotes IgE sensitization. Animal models confirm that early-life microbial disruption impairs immune tolerance at barrier sites (gut, lung, skin), with dysbiosis persisting up to 12–36 months post-exposure and causing lasting alterations in T- and B-cell responses to environmental allergens.
Confidence: moderate
Do fermented foods influence immune tolerance?
Fermented foods appear to promote immune tolerance by increasing gut microbiome diversity and reducing systemic inflammatory markers, with the strongest human evidence from a randomized trial (Wastyk et al., 2021, n=36) showing a 10-week high-fermented-food diet decreased 19 inflammatory proteins including IL-6 and reduced immune cell activation across 4 cell types. These effects are mediated through gut microbiome remodeling rather than direct microbial engraftment, with diversity gains persisting 4 weeks post-intervention. Preclinical and in vitro data further support Treg upregulation and Th2/Th17 suppression, though direct human quantification of Treg activity remains limited.
How it works
Lactic acid bacteria (LAB) and fermentation-derived metabolites—particularly short-chain fatty acids (SCFAs) and polyphenolics—modulate gut immune homeostasis by downregulating pro-inflammatory Th17 cytokines (e.g., IL-17F, IL-23), upregulating regulatory T-cells and IgA secretion, and reinforcing intestinal barrier integrity, collectively shifting immune tone away from pro-allergic Th2/Th17 dominance toward tolerance.
Confidence: low
Do fermented foods with live cultures (kefir, kimchi, sauerkraut) have a net benefit or harm on allergic rhinitis symptoms given their dual role as both histamine sources and probiotic vehicles?
The cumulative evidence from multiple systematic reviews and meta-analyses of probiotic RCTs (n>1,800 participants) supports a net clinical benefit of live-culture fermented foods and probiotic supplementation for allergic rhinitis, with improvements in nasal symptom scores and quality of life consistently reported. The probiotic-mediated immunomodulatory effects appear to outweigh the theoretical histamine burden in most individuals, though direct RCTs using whole fermented foods (kefir, kimchi, sauerkraut) specifically in AR populations remain scarce, with most evidence extrapolated from probiotic supplement trials. No studies have formally evaluated net benefit-harm balance in histamine-intolerant or DAO-deficient subgroups, leaving a clinically important safety question unanswered.
How it works
Probiotic strains in fermented foods (e.g., Lactobacillus and Bifidobacterium species) shift the Th1/Th2 immune balance toward Th1 dominance by upregulating IFN-γ and IL-12 while suppressing Th2 cytokines (IL-4, IL-5, IL-13), thereby reducing IgE class switching, mast cell degranulation, and eosinophil recruitment. Additionally, probiotic-induced regulatory T-cell expansion and short-chain fatty acid production via gut microbiota remodeling modulate the gut-lung immune axis, attenuating systemic allergic inflammation relevant to AR.
Confidence: moderate
Which dietary pattern changes most rapidly and durably shift the gut microbiome toward an allergy-protective composition?
High-fiber and Mediterranean dietary patterns most consistently shift the gut microbiome toward an allergy-protective composition, primarily by expanding SCFA-producing taxa such as Prevotella, Clostridia clusters, and Firmicutes while reducing opportunistic pathogens and mucin-degraders. SCFA production (particularly butyrate) can increase within days of adopting a high-fiber diet in general populations, but allergy-relevant immune changes such as Treg induction and IgE suppression appear to require sustained intervention over months. Durability after dietary cessation is poorly characterized, with animal models and mechanistic reviews suggesting that protective effects wane when the fermentable substrate is withdrawn.
How it works
Non-digestible carbohydrates (NDCs) from fiber-rich and Mediterranean diets are fermented by colonic bacteria into SCFAs, especially butyrate, which promote Foxp3+ Treg expansion, suppress Th2-skewed cytokines (IL-4, IgE), reinforce gut barrier integrity, and reduce allergen sensitization; polyphenols and omega-3 fatty acids in Mediterranean diets provide additional anti-inflammatory and prebiotic synergy. Low-fiber or Westernized diets deplete these taxa rapidly, favoring dysbiosis, increased gut permeability, and Th2 immune polarization underlying atopic disease.
Confidence: low
Does increased intestinal permeability (leaky gut) increase systemic allergen exposure and worsen pollen sensitisation or allergic rhinitis severity?
There is no direct clinical or mechanistic evidence from human studies linking increased intestinal permeability ('leaky gut') to enhanced systemic pollen exposure, worsened sensitisation, or greater allergic rhinitis (AR) severity. Available evidence instead focuses on gut dysbiosis associations with AR (altered beta-diversity, reduced SCFA-producing bacteria such as Faecalibacterium, increased pathobionts), without measuring barrier integrity markers such as zonulin, lactulose-mannitol ratios, or serum LPS. The theoretical pathway—whereby tight junction dysfunction permits allergen translocation, driving systemic Th2/IgE responses that amplify nasal inflammation—remains biologically plausible but empirically untested in AR-specific cohorts.
How it works
Disrupted epithelial tight junctions (mediated by zonulin upregulation or microbial dysbiosis) could theoretically permit translocation of undigested antigens or aeroallergens into the systemic circulation, promoting Th2 skewing, IgE class switching, and cytokine release (IL-4, IL-13, IL-25, IL-33, TSLP) that prime nasal mucosal responses; however, this cascade has been characterised mechanistically only in food allergy and asthma animal models, not in pollen sensitisation or AR.
Confidence: insufficient
Where the evidence runs out
Most evidence is observational or cross-sectional, limiting causal inference beyond Mendelian randomization findings; longitudinal studies tracking microbiome trajectories from infancy through allergic disease onset, as well as adequately powered RCTs testing SCFA supplementation or targeted probiotic interventions specifically for allergic rhinitis, remain scarce. Standardization of diversity metrics, sequencing methods, and allergy phenotyping across studies is also lacking, complicating direct comparisons. Large-scale, well-powered RCTs in adults using standardized outcome measures (e.g., TNSS, RQLQ) and strain-specific dosing protocols are lacking, making it difficult to establish causality or define clinical guidelines. Additionally, most mechanistic data derive from infant cohorts or animal models, limiting direct extrapolation to adult allergic rhinitis, and the causal directionality between specific taxa and disease (versus dysbiosis as a consequence of inflammation) remains incompletely resolved. Direct human intervention trials specifically targeting allergic rhinitis with SCFA supplementation are absent, leaving dose-response relationships, optimal SCFA formulations, and rhinitis-specific clinical endpoints undefined. The majority of mechanistic evidence derives from murine models, and it remains unclear whether observed preclinical effect sizes translate meaningfully to human allergic disease. Optimal probiotic strains, doses, and treatment durations remain unclear, with no consensus on which formulations are most effective for specific allergen sensitivities (e.g., birch vs. grass pollen). Larger, well-powered RCTs with standardized outcome measures, immune profiling, and long-term follow-up are needed to establish strain-specific recommendations and identify responder subgroups. Rhinitis-specific metagenomic data remain limited, with most studies reporting composite atopy or asthma outcomes rather than isolating allergic rhinitis as a distinct endpoint. Causal inference is constrained by the observational nature of cohort studies, and randomized intervention trials targeting early microbiome modulation for rhinitis prevention are largely absent. Causal inference remains limited because randomized controlled trials are ethically infeasible, and not all observational studies adequately control for confounding by indication (i.e., the infections requiring antibiotics may independently predispose to allergy). Additionally, the relative contributions of specific antibiotic classes, precise timing windows, and the reversibility of microbiome disruption through interventions such as probiotics are insufficiently characterized in humans. The pivotal human RCT was small (n=36, healthy adults only) with no allergic rhinitis-specific cohorts, and direct quantification of Tregs, allergen-specific IgE, or clinical allergy outcomes in atopic populations is absent from the current evidence base. Long-term trials in allergic individuals with standardized fermented food interventions and mechanistic immune endpoints are critically needed before conclusions can be extended to allergic disease management. No adequately powered RCTs directly compare whole fermented foods (kefir, kimchi, sauerkraut) versus probiotic supplements versus placebo in AR patients, meaning histamine co-exposure is never experimentally isolated. Critically, no studies have stratified outcomes by DAO enzyme activity or histamine intolerance status, leaving the net benefit-harm calculation unresolved for the subpopulation most likely to experience adverse effects from fermented food consumption. No published RCTs specifically measure the kinetics (days vs. weeks) or post-cessation durability of allergy-protective microbiome shifts in human atopic or allergic rhinitis cohorts, and no head-to-head dietary trials quantify Th1/Th2 cytokine rebalancing alongside microbial endpoints. Critical missing data include dose-response relationships for fiber intake, the relative contribution of fermented whole foods versus isolated prebiotics, and whether microbiome-mediated tolerance is achievable in already-sensitized adults versus only in early-life windows. No human study has quantified intestinal permeability (e.g., lactulose-mannitol ratios, serum zonulin, FITC-dextran) in AR patients versus controls, nor correlated barrier biomarkers with pollen-specific IgE titres or validated severity scores such as TNSS. Prospective studies combining gut permeability assays, allergen sensitisation panels, and nasal symptom outcomes are needed to establish whether leaky gut is a cause, consequence, or bystander in AR pathogenesis.
References
- 1.Simonyté Sjödin K, Vidman L, Rydén P, et al. · 2016 · Emerging evidence of the role of gut microbiota in the development of allergic diseases
- 2.Mousavian AH, ZareGarizi F, Ghoreshi B, et al. · 2024 · The association of infant and mother gut microbiomes with development of allergic diseases in children: a systematic review
- 3.Sasaki M, Suaini N, Afghani J, et al. · 2024 · Systematic review of the association between short-chain fatty acids and allergic diseases
- 4.Cait A, Hughes MR, Antignano F, et al. · 2017 · Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids
- 5.Luo C, Peng S, Li M, et al. · 2022 · The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis
- 6.Farahmandi K, Mohr A, McFarland L, et al. · 2022 · Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- 7.Sameeha F, Riaz S, Aslam M, et al. · 2025 · Association between early-life antibiotic exposure and gut microbiome alterations linked to allergic diseases in children: a systematic review
- 8.García-Mauriño Alcazar C, Paes VM, Shao Y, et al. · 2022 · The association between early-life gut microbiota and childhood respiratory diseases: a systematic review
- 9.Obiakor C, Tun H, Bridgman S, et al. · 2018 · The association between early life antibiotic use and allergic disease in young children: recent insights and their implications
- 10.Gallant RE, Reza S, Wiemels JL, et al. · 2025 · Microbiome and pediatric leukemia, diabetes, and allergies: Systematic review and meta-analysis
- 11.Spencer SJ, Silva EL, Benedetti Caffery E, et al. · 2022 · Fermented foods restructure gut microbiota and promote immune regulation via microbial metabolites
- 12.Yan SS, Ai S, Huang L, et al. · 2022 · Systematic review and meta-analysis of probiotics in the treatment of allergic rhinitis
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.
